Tag:
Herceptin
Latest Headlines
Latest Headlines
Roche dropping Herceptin price in India by 30%
Roche, whose patents have been under attack in India, is moving forward with plans to manufacture some drugs in the country, indicating it will drop the prices by as much as 50%, even as it faces a new threat from India's compulsory license law.
Roche bucks generics-erosion trend with 4% sales hike
Roche sales grew last year. So did core earnings, by a healthy 10%. But the Swiss drugmaker's executives weren't jumping for joy. In fact, they were quite measured in their outlook for 2013, predicting sales growth of about 4%, along the same lines as its 2012 results.
More ADC manufacturing capacity coming online
Targeted drugs are becoming the focus of a growing number of companies, and manufacturers are responding by building more antibody drug conjugate manufacturing capacity.
India to hit Roche, BMS with compulsory licenses on 3 cancer drugs
India is taking another swipe at Big Pharma. Three swipes, in fact: The government has started the process of granting three more compulsory licenses, this time on cancer treatments from Roche and Bristol-Myers Squibb. That means cheap copies of the on-patent drugs could soon hit the Indian market.
Roche looks to earn even more from Perjeta with EU nod
Roche tightened its lock on the breast cancer treatment market, and its expectations for many more billions of dollars in annual revenue, when an EU panel gave thumbs up for approval of Perjeta.
Roche gains blockbuster backing for breast cancer therapy in Europe
Roche moved a step closer to adding another gem to its crown as the leading provider of therapies against a form of breast cancer. European officials backed approval of the Swiss drug giant's Perjeta (pertuzumab) for use as part of a combo attack on HER2-positive breast cancers.
Roche sells insurance to gin up paying customers in China
While other drugmakers cut prices, set up access plans or wrangle with the Chinese government to sell products in that country, Roche ($RHHBY) is taking a more indirect tack. As Bloomberg reports, the Swiss drugmaker has teamed up with the reinsurer Swiss Re to sell private insurance to middle-class Chinese. That way, more patients can afford to use the company's pricey cancer drugs.
EMA probes Roche for faulty side-effects reporting
Did Roche ($RHHBY) bungle tens of thousands of adverse-event reports? European regulators aim to find out. The European Medicines Agency says it has started an "infringement procedure" against the Swiss drugmaker, to probe allegations that it dragged its feet on reporting potential side effects.
The 15 best-selling drugs of 2012
Some of the biggest blockbusters known to the pharma industry have dropped off the patent cliff and tumbled into the brutal land of generic therapies, where low-priced competition lays sales to...
Rise of the biologics has reshaped the list of top 15 drugs
Some of the biggest blockbusters known to the pharma industry have been swept off the patent cliff and tumbled into the brutal land of generic therapies, where low-priced competition awaits to chop up markets. Barring the development of new megablockbusters this list is likely to remain stable for some time. That's positive for the companies and their investors. It will also help fund major R&D operations around the globe. And the drive to improve performance should continue to drive innovation. Click here to check out the full report >>
- « first
- ‹ previous
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- next ›
- last »
